[33, 34, 35, 36] Mechanism: Typically pre-renal, occurring in the setting of volume depletion from GI losses (nausea, vomiting, diarrhea, reduced oral intake) More frequently seen at higher, obesity-level doses Although generally reno-protective long term, post-marketing data describe acute rises in creatinine following days to weeks of significant GI symptoms Risk factors: Underlying chronic kidney disease Concomitant use of ACE inhibitors, ARBs, diuretics, or SGLT2 inhibitors ED Management: IV fluids Hold GLP-1 and contributing medications Usually reversible with supportive care Future Directions GLP-1 receptor agonists are rapidly evolving beyond their original indications in diabetes and obesity
Talk with your doctor For more information about ways to manage low blood sugar while taking NovoLog, talk with your doctor
Weight loss pills, for which Novo and Lilly also have an edge, are likely to be another frontier opening, offering a new and more convenient way of delivering the medicines that are currently only available by injection
no need for higher doses or special timing considerations
Subcutaneous fat sits under the skin
Carefully handle glass ampoules to prevent contamination
